What is Van Nuys Prognostic Index?
The University of Southern California/Van Nuys Prognostic Index is an algorithm that quantifies five measurable prognostic factors known to be important in predicting local recurrence in conservatively treated patients with ductal carcinoma in situ (tumor size, margin width, nuclear grade, age, and comedonecrosis).
What is NPI in breast cancer?
The Nottingham prognostic index (NPI) is used to determine prognosis following surgery for breast cancer. Its value is calculated using three pathological criteria: the size of the tumour; the number of involved lymph nodes; and the grade of the tumour. It is calculated to select patients for adjuvant treatment.
How often does DCIS recur?
Most recurrences happen within the 5 to 10 years after initial diagnosis. The chances of a recurrence are under 30%. Women who have breast-conserving surgery (lumpectomy) for DCIS without radiation therapy have about a 25% to 30% chance of having a recurrence at some point in the future.
What is Oncotype DX DCIS?
The Oncotype DX DCIS test is a genomic test that analyzes the activity of a group of genes that can affect how DCIS is likely to behave and respond to treatment. The test is performed on a sample of DCIS tissue. The Oncotype DX DCIS test offers results as a recurrence score.
What is ductal carcinoma in situ?
Ductal carcinoma in situ (DCIS) means the cells that line the milk ducts of the breast have become cancer, but they have not spread into surrounding breast tissue. DCIS is considered non-invasive or pre-invasive breast cancer.
How is NPI score calculated?
NPI = maximum invasive cancer size (S) × 0.2 + lymph node stage (LN = 1, 2, or 3) + histological grade (H = 1, 2, or 3).
How do I calculate my NPI?
The NPI was calculated using the following formula: NPI=histological grade (1–3) (Rakha et al, 2008)+LN stage (1–3; 1=negative, 2=1–3 nodes positive, 3=⩾4 nodes positive)+(tumour size/cm × 0.2).
What does Oncotype score of 17 mean?
Recurrence Score of 0-15: The cancer has a low risk of recurrence. The benefits of chemotherapy likely will not outweigh the risks of side effects. Recurrence Score of 16-20: The cancer has a low to medium risk of recurrence.